Tardive dyskinesia: Analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America

Kasper, Siegfried; Lowry, A.; Hodge, Andrew; Bitter, István; Dossenbach, M.

doi:10.1016/j.schres.2005.07.032

Cited by 25 publications

(14 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although haloperidol may be more powerful than some atypicals, but is still a RG ''2'' medication, as the use of typical neuroleptics in higher dosages should be restricted to emergencies where parenteral administration is the only choice, and should be limited to a maximum of a few weeks, to avoid the risk of tardive dyskinesia (TD) (Kasper et al 2006). TD may have an increased incidence in bipolar patients (Hamra et al 1983;Mukherjee et al 1986;Kane 1999).…”

Section: How Do Antimanics Compare?mentioning

confidence: 99%

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania

Grunze

Vieta

Goodwin

et al. 2009

The World Journal of Biological Psychiatry

Self Cite

316

247

View full text Add to dashboard Cite

These updated guidelines are based on a first edition that was published in 2003, and have been edited and updated with the available scientific evidence until end of 2008. Their purpose is to supply a systematic overview of all scientific evidence pertaining to the treatment of acute mania in adults. The data used for these guidelines have been extracted from a MEDLINE and EMBASE search, from the clinical trial database clinicaltrials.gov, from recent proceedings of key conferences, and from various national and international treatment guidelines. Their scientific rigor was categorised into six levels of evidence (AÁF). As these guidelines are intended for clinical use, the scientific evidence was finally asigned different grades of recommendation to ensure practicability.

show abstract

Section: How Do Antimanics Compare?mentioning

confidence: 99%

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania

Grunze

Vieta

Goodwin

et al. 2009

The World Journal of Biological Psychiatry

Self Cite

316

247

View full text Add to dashboard Cite

show abstract

“…A large analysis of outpatients with schizophrenia in Africa, the Middle East, Asia, Eastern Europe and Latin America (including a total of 6981 patients) found a point prevalence of TD of 9%. 47 This is significantly higher than rates reported for patients on atypical antipsychotics in developed world contexts. 48 While it is well recognized that there is less risk of TD with the use of atypical antipsychotics, this complication is also not an inevitable outcome of classic antipsychotic therapy.…”

Section: Non-who Data On Outcomementioning

confidence: 80%

Dispelling a myth: developing world poverty, inequality, violence and social fragmentation are not good for outcome in schizophrenia

Burns

2009

Afr. J. Psych

View full text Add to dashboard Cite

The WHO multi-site studies of schizophrenia concluded that course and outcome of the disorder was better in developing countries. This has become psychiatric lore. However, the reality is that significant political, social and economic ills that characterize many countries in Africa, Latin America and Asia constitute psychosocial stressors that mediate strongly against better outcome in individuals living with this disorder. Outcome studies of schizophrenia in developing countries are reviewed and concepts of poverty, inequality and violence in relation to the course of the illness in this context are debated. The generally poor state of mental health services and policies in these regions are discussed. The belief that community and family life in the developing world is widely intact and that it provides a nurturing environment that facilitates recovery and promotes social and economic empowerment of seriously mentally ill individuals is dispelled as a myth. Idealisation of the under-developed South as a haven for schizophrenia sufferers will only add to the already heavy burden experienced by these individuals, their families and these societies in coping with this disabling disease.

show abstract

“…Probably the most important point is that SGAs are not all the same (Hartung et al, 2008;Stahl, 2000). They differ based on their pharmacodynamic properties, specifically with regard to the metabolic syndrome and the EPS side-effect profile (Kasper et al, 2006). Data are also available for halfyear administration of quetiapine for the indication of depression, but we do not have evidence for its long-term efficacy beyond this timespan.…”

Section: Discussionmentioning

confidence: 97%

The Role of Atypical Antipsychotics in Inadequate‐response and Treatment‐resistant Depression

Kasper

Akimova

Montgomery

2013

Treatment‐resistant Depression

Self Cite

View full text Add to dashboard Cite

Tardive dyskinesia: Analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America

Cited by 25 publications

References 18 publications

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania

Dispelling a myth: developing world poverty, inequality, violence and social fragmentation are not good for outcome in schizophrenia

The Role of Atypical Antipsychotics in Inadequate‐response and Treatment‐resistant Depression

Contact Info

Product

Resources

About